Barriers to Proceeding to Reduced-Intensity Allogeneic Stem Cell Transplant in Chronic Lymphocytic Leukemia
- *Corresponding Author:
- Samantha M Jaglowski, MD
A352 Starling-Loving Hall, 320 W. 10th Avenue
Columbus, OH 43210, USA
E-mail: [email protected]
Received date July 11, 2013; Accepted date August 30, 2013; Published date September 02, 2013
Citation: Jaglowski SM, Geyer S, Heerema NA, Elder P, Scholl D, et al. (2013) Barriers to Proceeding to Reduced-Intensity Allogeneic Stem Cell Transplant in Chronic Lymphocytic Leukemia. J Leuk (Los Angel) 1:121. doi:10.4172/2329-6917.1000121
Copyright: © 2013 Jaglowski SM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To identify potential barriers to reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (ASCT) in patients with chronic lymphocytic leukemia (CLL) we performed a retrospective review of patients referred for transplant consultation at our center. Of the 209 patients evaluated, a substantial proportion of patients who were appropriate candidates for RIC-ASCT were unable to attain disease control to proceed (18.3%) with this therapy. Fludarabine resistance at the time of consultation (p=0.026) and the presence of complex karyotype on metaphase cytogenetics (p=0.048) were observed more frequently among patients unable to receive a transplant, suggesting that the timing of transplant evaluation earlier in the course of treatment for high risk genomic patients is critical for being able to incorporate this treatment modality.